Cabio Biotech (Wuhan) Co., Ltd.

SHSE:688089 Stock Report

Market Cap: CN¥3.5b

Cabio Biotech (Wuhan) Balance Sheet Health

Financial Health criteria checks 5/6

Cabio Biotech (Wuhan) has a total shareholder equity of CN¥1.5B and total debt of CN¥17.2M, which brings its debt-to-equity ratio to 1.1%. Its total assets and total liabilities are CN¥1.7B and CN¥123.2M respectively. Cabio Biotech (Wuhan)'s EBIT is CN¥98.6M making its interest coverage ratio -30.9. It has cash and short-term investments of CN¥158.6M.

Key information

1.1%

Debt to equity ratio

CN¥17.19m

Debt

Interest coverage ratio-30.9x
CashCN¥158.64m
EquityCN¥1.54b
Total liabilitiesCN¥123.19m
Total assetsCN¥1.66b

Recent financial health updates

No updates

Recent updates

We Think That There Are Issues Underlying Cabio Biotech (Wuhan)'s (SHSE:688089) Earnings

Nov 04
We Think That There Are Issues Underlying Cabio Biotech (Wuhan)'s (SHSE:688089) Earnings

Cabio Biotech (Wuhan) (SHSE:688089) Might Be Having Difficulty Using Its Capital Effectively

Oct 28
Cabio Biotech (Wuhan) (SHSE:688089) Might Be Having Difficulty Using Its Capital Effectively

Subdued Growth No Barrier To Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) With Shares Advancing 31%

Oct 01
Subdued Growth No Barrier To Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) With Shares Advancing 31%

There's Reason For Concern Over Cabio Biotech (Wuhan) Co., Ltd.'s (SHSE:688089) Massive 25% Price Jump

Aug 06
There's Reason For Concern Over Cabio Biotech (Wuhan) Co., Ltd.'s (SHSE:688089) Massive 25% Price Jump

Cabio Biotech (Wuhan) (SHSE:688089) Could Be Struggling To Allocate Capital

Jun 07
Cabio Biotech (Wuhan) (SHSE:688089) Could Be Struggling To Allocate Capital

Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected

May 06
Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected

Cabio Biotech (Wuhan)'s (SHSE:688089) Promising Earnings May Rest On Soft Foundations

May 03
Cabio Biotech (Wuhan)'s (SHSE:688089) Promising Earnings May Rest On Soft Foundations

The Market Lifts Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Shares 27% But It Can Do More

Mar 21
The Market Lifts Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Shares 27% But It Can Do More

Financial Position Analysis

Short Term Liabilities: 688089's short term assets (CN¥672.3M) exceed its short term liabilities (CN¥108.0M).

Long Term Liabilities: 688089's short term assets (CN¥672.3M) exceed its long term liabilities (CN¥15.2M).


Debt to Equity History and Analysis

Debt Level: 688089 has more cash than its total debt.

Reducing Debt: 688089's debt to equity ratio has increased from 0% to 1.1% over the past 5 years.

Debt Coverage: 688089's debt is well covered by operating cash flow (870%).

Interest Coverage: 688089 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies